Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

Abstract Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4 + subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2014-03, Vol.268 (1), p.95-98
Main Authors: Sato, Douglas Kazutoshi, Nakashima, Ichiro, Bar-Or, Amit, Misu, Tatsuro, Suzuki, Chihiro, Nishiyama, Shuhei, Kuroda, Hiroshi, Fujihara, Kazuo, Aoki, Masashi
Format: Article
Language:English
Subjects:
Allergy and Immunology
Cell Separation
Female
Fingolimod
Fingolimod Hydrochloride
Flow Cytometry
Humans
Immunosuppressive Agents - therapeutic use
Interleukin-17
Male
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - blood
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - immunology
Neurology
Propylene Glycols - therapeutic use
Regulatory T cells
Sphingosine - analogs & derivatives
Sphingosine - therapeutic use
T-Lymphocytes, Regulatory - immunology
Th17
Th17 Cells - immunology
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Fingolimod has demonstrated efficacy in patients with multiple sclerosis (MS), and patients become gradually lymphopenic after a few days of treatment, with selective reductions in CD4 + subsets. We observed an increase in the frequencies of circulating regulatory T cells after fingolimod administration. However, we also found that half of patients had increased proportion of circulating Th17 cells in CD4 + T cells after treatment (including a patient with MS relapses), whereas the others showed lower frequencies of Th17 cells, indicating some variability among patients. Further studies may confirm if slower reduction of circulating Th17 cells following fingolimod initiation predisposes to relapses.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2014.01.008